📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Morepen Laboratories Repays ₹99 Crore Credit Facility to Kotak Mahindra Bank
Morepen Laboratories has successfully repaid its entire credit facility totaling ₹99 crore to Kotak Mahindra Bank. The facility consisted of a ₹79 crore working capital demand loan and a ₹20 crore cash credit limit. The repayment was effective as of March 2, 2026, and the bank is now in the process of releasing the assets previously held as security. This move signifies improved liquidity and a commitment to deleveraging the balance sheet.
Key Highlights
Full repayment of ₹99 crore credit facility to Kotak Mahindra Bank completed
Facility included ₹79 crore working capital demand loan and ₹20 crore cash credit
Repayment effective from March 2, 2026, with No Dues Certificate in process
Release of charged assets will improve the company's financial flexibility
💼 Action for Investors
This is a positive development indicating strong internal accruals and debt reduction. Investors should look for a reduction in interest expenses in the upcoming quarterly financial statements.
Morepen Labs Secures ₹30 Crore Unsecured Working Capital Loan from KEB Hana Bank
Morepen Laboratories has entered into an agreement with KEB Hana Bank to avail an unsecured working capital term loan of ₹30 crore. The loan carries a competitive interest rate of 7.30% per annum (Repo + 2.05%) and has a tenure of 3 years, including a 6-month moratorium. This facility is backed by a personal guarantee from the Promoter and CMD, Mr. Sushil Suri. The company's existing debt, excluding this new facility, stands at ₹164.62 crore.
Key Highlights
Execution of a ₹30 crore unsecured working capital term loan facility with KEB Hana Bank.
Interest rate set at prevailing repo rate + 2.05%, currently effective at 7.30% per annum.
Loan tenure of 3 years with a 6-month moratorium and 5 half-yearly equal installments.
Personal guarantee provided by Promoter, Chairman & Managing Director Mr. Sushil Suri.
Total outstanding debt of the company (excluding this loan) is ₹164.62 crore as of March 10, 2026.
💼 Action for Investors
Investors should monitor the company's debt-to-equity ratio and ensure that the additional working capital effectively supports revenue growth. The promoter's personal guarantee is a positive sign of internal confidence in the company's repayment capacity.
Morepen Labs Bags ₹825 Crore Global CDMO Order from International Pharma Major
Morepen Laboratories has secured a significant international commercial supply contract worth approximately ₹825 crore (USD 91 million) from a leading global pharmaceutical company. This deal marks a major strategic expansion into the high-growth CDMO segment, with supplies expected to commence within the next 4-5 months. The contract is scheduled for execution over a 12-15 month period, concluding by Q1 of the following fiscal year. This order represents a substantial revenue opportunity and a shift towards higher-margin manufacturing services.
Key Highlights
Secured a ₹825 crore (USD 91 million) international CDMO contract from a global pharma major
Execution timeline set for 12-15 months with supplies starting in 4-5 months
Strategic entry into the high-margin Contract Development and Manufacturing Organization (CDMO) segment
Contract includes both development and manufacturing services for the international market
💼 Action for Investors
Investors should view this as a major growth catalyst that significantly improves revenue visibility and potential margins. Monitor the commencement of supplies in the next two quarters to ensure execution remains on track.
Morepen Labs Board Approves Rs 50 Crore Unsecured Term Loan from Woori Bank
The Finance Committee of Morepen Laboratories has approved a proposal to avail an unsecured term loan facility of Rs 50 crore from Woori Bank. This capital infusion is intended to support the company's financial requirements, though specific end-use details were not disclosed in the initial filing. The loan is notable for being unsecured, meaning no company assets are pledged as collateral for this specific facility. Investors should await further disclosures regarding interest rates and repayment schedules once the formal loan documents are executed.
Key Highlights
Approved an unsecured term loan facility aggregating to Rs 50 crore
Facility to be provided by Woori Bank
Approval granted by the Finance Committee of the Board on February 11, 2026
Loan agreement and related documentation to be executed in due course
💼 Action for Investors
Investors should monitor the company's upcoming disclosures for the interest rate on this loan and how the funds will be deployed to ensure it generates a return higher than the cost of debt.
Morepen Labs Q3 FY26: Consolidated PAT Jumps 83% QoQ to ₹28 Cr; Medical Devices Up 44% YoY
Morepen Laboratories reported a strong Q3 FY26 with consolidated revenue reaching ₹488 crore, a 17% growth over the previous quarter. The Medical Devices segment emerged as the primary growth engine, surging 44% YoY to ₹177 crore, driven by high demand for glucometers and BP monitors. While the Pharma business remained relatively flat at ₹285 crore, significant operational efficiencies led to a consolidated EBITDA growth of 42% QoQ. The company continues to strengthen its leadership in the home diagnostics market with a cumulative base of 16.85 million glucometers sold.
Key Highlights
Consolidated PAT surged 83% QoQ to ₹28 crore, while EBITDA grew 42% QoQ to ₹50 crore.
Medical Devices revenue grew 44% YoY to ₹177 crore, now contributing 38% of the total business mix.
Glucometer revenue increased 40% YoY to ₹134 crore, supported by a massive base of 2.33 billion test strips sold.
Standalone gross revenue for Q3 FY26 stood at ₹462 crore, marking a 13% YoY increase.
API business remains the largest segment (62% share) with Atorvastatin leading the product mix at 26%.
💼 Action for Investors
Investors should monitor the continued scaling of the high-growth Medical Devices segment, which is successfully diversifying the company's revenue away from pure APIs. The sharp improvement in quarterly margins and net profit suggests a positive trend in operational leverage.
Morepen Labs Q3 FY26 Results: Revenue Up 7% Y-o-Y to ₹484 Cr, Net Profit at ₹27.5 Cr
Morepen Laboratories reported a steady performance for Q3 FY26, with consolidated revenue from operations growing 6.9% year-on-year to ₹484.16 crore. The consolidated net profit for the quarter stood at ₹27.51 crore, a marginal increase from ₹26.69 crore in the previous year's corresponding quarter. Operating performance showed strength as Profit Before Tax (before exceptional items) rose by 15.2% Y-o-Y to ₹31.69 crore. Investors should note that Dr. Morepen Limited ceased to be a subsidiary on July 31, 2025, which impacts the year-to-date consolidated comparisons.
Key Highlights
Consolidated Revenue from operations increased to ₹484.16 crore in Q3 FY26 from ₹452.78 crore in Q3 FY25.
Profit Before Tax (before exceptional items) grew 15.2% Y-o-Y to ₹31.69 crore.
Net Profit for the quarter reached ₹27.51 crore compared to ₹26.69 crore in the same period last year.
Total Income for the nine-month period ended Dec 2025 stood at ₹1,333.82 crore.
Divestment of Dr. Morepen Limited (stake reduced to 19.96%) completed during the fiscal year, shifting it to an investment status.
💼 Action for Investors
The steady growth in core operating profit despite the divestment of the consumer health subsidiary suggests improved focus on the pharmaceutical segment. Investors should monitor the company's margin expansion in the upcoming quarters as the new corporate structure stabilizes.
Morepen Labs Obtains High Court Stay on ₹117.94 Crore GST Show Cause Notice
Morepen Laboratories has received a favorable interim order from the Himachal Pradesh High Court, which has stayed a Show Cause Notice (SCN) issued by the GST department. The SCN, dated December 2, 2025, alleged that the company erroneously claimed GST refunds totaling ₹117.94 crore. By obtaining this stay, the company has successfully halted the immediate operation of the tax demand. While the legal matter remains pending, the stay prevents any immediate financial outflow or operational disruption related to this specific tax claim.
Key Highlights
Himachal Pradesh High Court granted a stay on the operation of a GST Show Cause Notice dated December 2, 2025.
The tax authority had alleged an erroneous GST refund claim amounting to ₹117,94,03,452.
The company challenged the notice through a writ petition, resulting in the court order dated January 6, 2026.
Management confirms there is currently no impact on financials or operations due to the grant of the stay.
The dispute pertains to Section 54 of the CGST Act and Rule 89 regarding refund mechanisms.
💼 Action for Investors
Investors should monitor the final outcome of the writ petition as the stay is an interim relief against a significant potential liability. The news is positive in the short term as it removes immediate financial pressure on the company's balance sheet.
Morepen Labs Receives Show Cause Notice Regarding GST Refund Claim
Morepen Laboratories has received a Show Cause Notice (SCN) from the GST Authority regarding a GST refund claim. The SCN alleges that the company erroneously claimed excess GST refund amounting to ₹117,94,03,452 under Section 54 of the CGST Act, 2017. The company had applied for refund of accumulated ITC on account of zero rated supply for the financial years 2020 to 2024. Morepen Labs contends that it claimed the refund as per GST Act provisions and will submit necessary information to the GST authority.
Key Highlights
SCN received from GST Authority on December 3, 2025
Alleged excess GST refund claim of ₹117,94,03,452
SCN relates to financial years 2020-21, 2021-22, 2022-23 and 2023-24
Company applied for refund under Rule 89(4) instead of Rule 89(4B) of CGST Rules, 2017
💼 Action for Investors
Investors should monitor the outcome of this legal matter and its potential financial implications. While the company believes the SCN has no merit, the final liability, if any, is yet to be ascertained.